Lundbeck completed the acquisition of Longboard Pharmaceuticals for $2.5bn.

Lundbeck, a Danish international pharmaceutical company, completed the acquisition of Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company, for $2.5bn. “We are very pleased to reach today’s milestone at the earliest opportunity and to welcome Longboard into Lundbeck. In just a few years, the Longboard team has achieved remarkable results, and with the transaction now complete we are adding a highly innovative project in an area of significant unmet medical need to our portfolio. The acquisition of Longboard advances our Focused Innovator strategy to transform the lives of patients suffering from severe brain disorders and drive sustainable long-term growth," Charl van Zyl, Lundbeck President and CEO.